Oculis Holding AG
Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024. In the quarter to June 2026, revenue grew 24.0%, EPS grew 66.1%, free cash flow fell 10.4% and total debt rose 159.8%, each against the same quarter a year earlier.
Follow OCS
Oculis Holding AG (OCS) EV/Sales
As of 16 October 2026, Oculis Holding AG (OCS) trades at a EV/Sales of 109×. Over the past ten years it has ranged from 0.0× (March 2024) to 1,176× (May 2026); the current reading is higher than 53% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 545× | (26.28%) |
| FY2024 | 739× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 383× | (58.42%) |
| Mar 2026 | 920× | 68.87% |
| Dec 2025 | 545× | (30.81%) |
| Sep 2025 | 788× | (14.89%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ARVN Arvinas, Inc. compare | −0.4× |
| MPLT MapLight Therapeutics, Inc. compare | n/m |
| EPRX Eupraxia Pharmaceuticals Inc. compare | n/m |
| RGNX REGENXBIO Inc. compare | 1.5× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.6× |
| ALLO Allogene Therapeutics, Inc. compare | 20.9× |
| OCS Oculis Holding AG | 109× |
| CBIO Crescent Biopharma, Inc. compare | 187× |
| ALT Altimmune, Inc. compare | 2,534× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)